All Stories

  1. An Exceptional Case of Recall Phenomenon to Hypersensitivity to Amoxicillin
  2. Contact Palpebral Dermatitis and Conjunctivitis Due to Delayed Hypersensitivity to Timolol
  3. Impact of the ERS/ATS 2021 guidelines for lung function interpretation on assessing the response to biologics in asthma
  4. Burden of refractory and unexplained chronic cough on patients’ lives: a cohort study
  5. Transcriptomics reveals new regulatory mechanisms involved in benralizumab response
  6. Correspondence regarding the paper “Laorden D, Zamarrón E, Romero D, Domínguez-Ortega J, Villamañán E, Losantos I, Gayá F, Quirce S, Álvarez-Sala R. Evaluation of FEOS score and super-responder criteria in a real-life cohort treated with anti-IL5/IL5R....
  7. Interleukin 5 Receptor Subunit Alpha Expression as a Potential Biomarker in Patients with Nasal Polyposis
  8. Role of Different Health Care Professionals in the Management of Asthma Patients: The GEMA-FORUM IV Task Force
  9. Report of two sisters with Netherton syndrome successfully treated with dupilumab and review of the literature
  10. ALERGODATA: Sentinel registry of health outcomes in allergic patients treated with biological therapies from specialized allergology clinics in Spain
  11. Characteristics and Management of Patients with Refractory or Unexplained Chronic Cough in Outpatient Hospital Clinics in Spain: A Retrospective Multicenter Study
  12. Avances en el manejo del asma difícil de tratar y asma grave
  13. A Prospective Study of Costs Associated With the Evaluation of Allergic Reactions to Radiological Contrast Media
  14. Quantitative and qualitative methods of evaluating response to biologics in severe asthma patients: Results from a real-world study
  15. Sensitization Phenotypes in Immediate Hypersensitivity to Cephalosporins: A Cluster Analysis Study
  16. Severity and duration of allergic conjunctivitis: are they associated with severity and duration of allergic rhinitis and asthma?
  17. RNY3 modulates cell proliferation and IL13 mRNA levels in a T lymphocyte model: a possible new epigenetic mechanism of IL-13 regulation
  18. Management of United Airway Disease Focused on Patients With Asthma and Chronic Rhinosinusitis With Nasal Polyps: A Systematic Review
  19. Response to monoclonal antibodies in asthma: definitions, potential reasons for failure and therapeutic options for suboptimal response
  20. Changes in Sensitization Patterns in the Last 25 Years in 619 Patients with Confirmed Diagnoses of Immediate Hypersensitivity Reactions to Beta-Lactams
  21. Cluster Subanalysis of Patients With Severe Asthma Who Responded to Omalizumab
  22. Environmental drivers of the seasonal exposure to airborne Alternaria spores in Spain
  23. Dupilumab: A Review of Present Indications and Off-Label Uses
  24. Polymorphisms in Human IL4, IL10, and TNF Genes Are Associated with an Increased Risk of Developing NSAID-Exacerbated Respiratory Disease
  25. Hypersensitivity to Gadolinium-Based Contrast Media
  26. Effective Management of Severe Asthma with Biologic Medications in Adult Patients: A Literature Review and International Expert Opinion
  27. Effects of Therapeutic Antibodies on Gene and Protein Signatures in Asthma Patients: A Comparative Systematic Review
  28. Patterns of Cross-Reactivity in Patients With Immediate Hypersensitivity Reactions to Gadobutrol
  29. Integration of in vitro allergy test results and ratio analysis for the diagnosis and treatment of allergic patients (INTEGRA)
  30. PTGDR2 Expression in Peripheral Blood as a Potential Biomarker in Adult Patients with Asthma
  31. Delayed Reaction to Gadobutrol in a Nurse With Myocarditis After SARS-Cov-2 Infection
  32. Genetics and Epigenetics of Nasal Polyposis: A Systematic Review
  33. Reply to “Delayed hypersensitivity reactions to piperacillin-tazobactam”
  34. ARADyAL: The Spanish Multidisciplinary Research Network for Allergic Diseases
  35. Increased TPSAB1 Copy Number in a Family With Elevated Basal Serum Levels of Tryptase
  36. Clinical Recommendations for the Management of Biological Treatments in Severe Asthma Patients: A Consensus Statement
  37. A Comprehensive Prospective Study of the Costs Associated With Evaluation of ß-Lactam Allergy
  38. Molecular Analysis of IL-5 Receptor Subunit Alpha as a Possible Pharmacogenetic Biomarker in Asthma
  39. Real‐life study in non‐atopic severe asthma patients achieving disease control by omalizumab treatment
  40. Pollen-Induced Allergic Asthma and Rhinoconjunctivitis: Differences in Outcome Between Seasonal and Nonseasonal Exposure to Allergens Under Real-Life Conditions (The LANDSCAPE Study)
  41. Analysis of the Costs Associated With the Elective Evaluation of Patients Labelled as Allergic to Beta-Lactams or Nonsteroidal Antiinflamatory Agents
  42. Precision Medicine in House Dust Mite-Driven Allergic Asthma
  43. Usefulness of an Artificial Neural Network in the Prediction of β-Lactam Allergy
  44. Sensitization phenotypes in immediate reactions to piperacillin-tazobactam
  45. Development of a tool to measure the clinical response to biologic therapy in uncontrolled severe asthma: the FEOS score.
  46. A Prospective Study of Costs Associated with the Evaluation of β-Lactam Allergy in Children
  47. Cheilitis Associated With Sensitization to Penicillium notatum in a Clarinetist
  48. Urban atmospheric levels of allergenic pollen: comparison of two locations in Salamanca, Central-Western Spain
  49. <p>FENOMA Study: Achieving Full Control in Patients with Severe Allergic Asthma</p>
  50. COVID-19, asthma, and biological therapies: What we need to know
  51. Promoter Genotyping and mRNA Expression – Based Analysis of the PTGDR Gene in Allergy
  52. Genetics and Epigenetics of Atopic Dermatitis: An Updated Systematic Review
  53. Atopy Can Be an Interfering Factor in Genetic Association Studies of ß-Lactam Allergy
  54. A prospective study of costs associated to the evaluation of non‐steroidal anti‐inflammatory hypersensitivity reactions
  55. Severe asthma phenotypes in patients controlled with omalizumab: A real-world study
  56. Relationship between CRTH2 mRNA expression in peripheral blood and IgE and eosinophil levels in adult patients with asthma
  57. Defects in memory B-cell and plasma cell subsets expressing different immunoglobulin-subclasses in patients with CVID and immunoglobulin subclass deficiencies
  58. YRNAs overexpression and potential implications in allergy
  59. Severe asthma: Entering an era of new concepts and emerging therapies: Highlights of the 4th international severe asthma forum, Madrid, 2018
  60. Adjuvants in Allergen-Specific Immunotherapy: Modulating and Enhancing the Immune Response
  61. Benralizumab: A New Approach for the Treatment of Severe Eosinophilic Asthma
  62. PTGDR expression is upregulated through retinoic acid receptors (RAR) mechanism in allergy
  63. Selection of Biologics in Severe Asthma: A Multifaceted Algorithm
  64. Tolerability of iobitridol in patients with non-immediate hypersensitivity reactions to iodinated contrast media
  65. A case report of fixed drug eruption caused by several drugs because of cross-reactivity and co-sensitization
  66. Adherence to Anaphylaxis Guidelines: Real-World Data From the Emergency Department of a Tertiary Hospital
  67. Dupilumab: A New Paradigm for the Treatment of Allergic Diseases
  68. Resolution of Type IV Hypersensitivity After Bone Marrow Transplantation
  69. Cluster Analysis Identifies 3 Phenotypes within Allergic Asthma
  70. Molecular sensitization patterns and influence of molecular diagnosis in immunotherapy prescription in children sensitized to both grass and olive pollen
  71. Consensus document on dog and cat allergy
  72. Allergic rhinitis severity can be assessed using a visual analogue scale in mild, moderate and severe
  73. Phenotypes related with clinical improvement of omalizumab-treated patients in routine clinical practice. FENOMA Study
  74. Economic costs of severe asthma in omalizumab-treated patients. FENOMA Study
  75. Pharmacogenetics and the treatment of asthma
  76. Reproduction of the atopic march in an adult after allogeneic bone marrow transplantation from an atopic sibling
  77. dIvergEnt: How IgE Axis Contributes to the Continuum of Allergic Asthma and Anti-IgE Therapies
  78. Acute generalized exanthematous pustulosis (AGEP) induced by azithromycin
  79. Allergic respiratory disease: Different allergens, different symptoms
  80. Omalizumab Is Equally Effective in Persistent Allergic Oral Corticosteroid-Dependent Asthma Caused by Either Seasonal or Perennial Allergens: A Pilot Study
  81. Estimate of the total costs of allergic rhinitis in specialized care based on real-world data: the FERIN Study
  82. Performance in real life of the European Network on Drug Allergy algorithm in immediate reactions to beta-lactam antibiotics
  83. Allergic rhinitis causes loss of smell in children: The OLFAPEDRIAL study
  84. Predictive models in drug allergy: An appropriate patient selection is needed
  85. Retinoic Acid Modulates PTGDR Promoter Activity
  86. Filaggrin gene mutations and new SNPs in asthmatic patients: a cross-sectional study in a Spanish population
  87. Relationship between respiratory and food allergy and evaluation of preventive measures
  88. Comparison of Pollen Levels Between 2 Pollen Traps in Salamanca, Spain
  89. Effectiveness of omalizumab in severe solar urticaria
  90. Applications of Molecular Genetics to the Study of Asthma
  91. Analysis of FOXP3 gene in children with allergy and autoimmune diseases
  92. Genome-wide association studies (GWAS) and their importance in asthma
  93. First case of airborne-induced anaphylaxis triggered by fruit
  94. Implications of cytokine genes in allergic asthma
  95. Genome-wide expression profiling of B lymphocytes reveals IL4R increase in allergic asthma
  96. Olive, grass or both? Molecular diagnosis for the allergen immunotherapy selection in polysensitized pollinic patients
  97. Characterization of a complex CYP2D6 genotype that caused an AmpliChip CYP450 Test® no-call in the clinical setting
  98. Types of sensitization to aeroallergens: definitions, prevalences and impact on the diagnosis and treatment of allergic respiratory disease
  99. Diagnostic and therapeutic approaches in respiratory allergy are different depending on the profile of aeroallergen sensitisation
  100. Is faster safer? Cluster versus short conventional subcutaneous allergen immunotherapy
  101. Analysis of comorbidities and therapeutic approach for allergic rhinitis in a pediatric population in Spain
  102. Bilastine for the treatment of urticaria
  103. Tryptase: Genetic and functional considerations
  104. Reply
  105. Validation of the modified allergic rhinitis and its impact on asthma (ARIA) severity classification in allergic rhinitis children: the PEDRIAL study
  106. Aeroallergen Sensitization Influences Quality of Life and Comorbidities in Patients with Nasal Polyposis
  107. Reply
  108. The impact of allergic rhinitis on symptoms, and quality of life using the new criterion of ARIA severity classification
  109. Fixed drug eruption caused by etoricoxib with tolerance to celecoxib and parecoxib
  110. Measurement of asthma control according to global initiative for asthma guidelines: a comparison with the asthma control questionnaire
  111. Epigenetic changes in B lymphocytes associated with house dust mite allergic asthma
  112. PTGDR gene in asthma: a functional, genetic, and epigenetic study
  113. Immediate allergic reactions to β-lactams: Diagnostic accuracy of skin tests
  114. Validation of ARIA (Allergic Rhinitis and its Impact on Asthma) classification in a pediatric population: The PEDRIAL study
  115. Drug rash with eosinophilia and systemic symptoms (DRESS) after an unrelated donor BM transplant
  116. Airborne pollen calendar of Salamanca, Spain, 2000–2007
  117. Discrimination between moderate and severe disease may be used in patients with either treated or untreated allergic rhinitis
  118. Immunological aspects of nonimmediate reactions to β-lactam antibiotics
  119. Validation of ARIA duration and severity classifications in Spanish allergic rhinitis patients - The ADRIAL cohort study
  120. Do genetic factors determine atopy or allergy?
  121. Epigenetic aspects of the allergic diseases
  122. Component‐resolved diagnosis of pollen allergy based on skin testing with profilin, polcalcin and lipid transfer protein pan‐allergens
  123. Efficacy of desloratadine in intermittent allergic rhinitis: a GA2LEN study
  124. Recurring eczema during pregnancy and after delivery due to sensitization caused by an ultrasound gel
  125. Chronic urticaria: do urticaria nonexperts implement treatment guidelines? A survey of adherence to published guidelines by nonexperts
  126. A new PTGDR promoter polymorphism in a population of children with asthma
  127. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients
  128. Hypersensitivity reactions to cephalosporins
  129. Molecular Analysis of Activation-Induced Cytidine Deaminase Gene in Immunoglobulin-E Deficient Patients
  130. Therapeutic Applications of Antisense Oligonucleotides in Asthma and Allergy
  131. Development and Validation of a New Spanish Instrument to Measure Health-Related Quality of Life in Patients with Allergic Rhinitis: The ESPRINT Questionnaire
  132. Usefulness of intradermal test and patch test in the diagnosis of nonimmediate reactions to metamizol
  133. Proteomic approaches for identifying new allergens and diagnosing allergic diseases
  134. A new criterion by which to discriminate between patients with moderate allergic rhinitis and patients with severe allergic rhinitis based on the Allergic Rhinitis and its Impact on Asthma severity items
  135. Prevention of allergic diseases
  136. Promoter genetic variants of prostanoid DP receptor (PTGDR) gene in patients with asthma
  137. Interleukin-4 (IL4) and Interleukin-4 receptor (IL4RA) polymorphisms in asthma: a case control study
  138. El polimorfismo Q576R del gen IL4RA se asocia con valores elevados de IgE total en pacientes con antecedentes familiares de atopia
  139. Analysis of the leukotriene C4 synthase A−444C promoter polymorphism in a Spanish population
  140. Tick-bite-induced anaphylaxis in Spain
  141. Infección vírica y asma: mecanismos inmunológicos
  142. Interacción de isoniazida con alimentos
  143. Anaphylactic reaction to ranitidine
  144. Cross‐reactivity between quinolones
  145. Occupational protein contact dermatitis from herring
  146. Fixed eruption caused by ciprofloxacin with cross‐sensitivity to norfloxacin
  147. Hypersensitivity to trimethoprim
  148. Urticaria from caffeine